Evidence Snapshot

Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta

CHEMBL3430899 PROTEIN COMPLEX Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:23Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 6:25 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL3430899

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta as ChEMBL target CHEMBL3430899, mapped to UniProt P28472. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta

PROTEIN COMPLEX · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL3430899

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P28472

Gamma-aminobutyric acid receptor subunit beta-3

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta matters

As of 2026-09-13

Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta is reviewed as Gamma-aminobutyric acid receptor subunit beta-3 (UniProt P28472); Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta shows late clinical disease relevance led by Angelman syndrome. 3 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 50 compounds, and 3 assays, with lead potency reaching pChEMBL 8.0.

Protein context

Gamma-aminobutyric acid receptor subunit beta-3

Gamma-aminobutyric acid receptor subunit beta-3 Sequence length is 473 aa.

Review this target as Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta, mapped to UniProt P28472. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit beta-3. Sequence length is 473 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P28472 Protein

Disease context

Angelman syndrome

Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta shows late clinical disease relevance led by Angelman syndrome. 3 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include GABOXADOL.

Start review with Angelman syndrome because it currently carries late clinical support. Linked drugs include GABOXADOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Late clinical 1 linked drug

Activity base

Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 50 compounds, and 3 assays for this target. The dominant activity type is EC50. CHEMBL5612649 is the current potency anchor at pChEMBL 8.0.

Use CHEMBL5612649 as the tractability anchor when discussing potency (pChEMBL 8.0).

Activity source · ChEMBL 36 via Core Engine

2 approved pChEMBL 8.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P28472, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Angelman syndrome is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

Total Compounds

Total Assays

Approved Drugs

EC50: 51.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5612649	8.0	EC50	—
No preferred name CHEMBL5613388	7.7	EC50	—
No preferred name CHEMBL5612974	7.6	EC50	—
No preferred name CHEMBL5612194	7.5	EC50	—
No preferred name CHEMBL5613759	7.5	EC50	—